Iaquinta Maria Rosa, De Pace Raffaella, Benkhalqui Assia, D'Agostino Antonio, Trevisiol Lorenzo, Finotti Alessia, Breveglieri Giulia, Tognon Mauro, Martini Fernanda, Mazzoni Elisa
Laboratories of Cell Biology and Molecular Genetics, Section of Experimental Medicine, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy.
Center for Studies on Gender Medicine, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy.
Int J Mol Sci. 2025 Apr 17;26(8):3807. doi: 10.3390/ijms26083807.
Bone diseases represent a growing healthcare challenge due to population aging and lifestyle changes. Although bone has a natural regenerative capacity, approximately 10% of fractures fail to heal properly, requiring advanced therapeutic approaches. Bone tissue engineering (BTE) has advanced the use of osteoinductive and osteoconductive biomaterials to support bone regeneration. Among them, Bio-Oss Collagen, a composite of bovine hydroxyapatite and collagen, has shown excellent biocompatibility and bioactivity properties. This study analyzes the effect of Bio-Oss Collagen on human bone marrow-derived mesenchymal stem cells (hBMSCs), assessing its osteoinductive and immunomodulatory potential. After 7 days of culture, the biomaterial modulated the expression of key genes involved in osteogenesis and chondrogenesis, which are known for their role in bone formation and maturation. At the same time, a downregulation of genes associated with bone resorption was observed. Secretome analysis revealed a controlled release of pro-regenerative cytokines, suggesting a role of the biomaterial in modulating inflammation to promote bone regeneration. Furthermore, immunofluorescence confirmed the high expression of osteocalcin and osteopontin, which are key markers of bone mineralization. These findings indicate that Bio-Oss Collagen supports osteogenesis and modulates the immune response, creating a microenvironment favorable for bone regeneration.
J Biomed Mater Res A. 2020-3
ACS Appl Mater Interfaces. 2024-10-23
MedComm (2020). 2024-7-24
Biologics. 2024-1-25
Inflamm Regen. 2023-5-25
Front Bioeng Biotechnol. 2022-6-27
Biochem Pharmacol. 2022-3
Semin Cell Dev Biol. 2022-3